Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13495375 | 0.85 | CYP19A1 (0.45) | KMT2ATSHRMEN1L3MBTL1CYP19A1 | |
| SCHEMBL13495329 | 0.83 | KMT2A (0.46) | KMT2ATSHRMEN1L3MBTL1CYP19A1 | |
| SCHEMBL13495367 | 0.83 | GPBAR1 (0.50) | KMT2ATSHRMEN1SMN1; SMN2CYP19A1 | |
| SCHEMBL65809 | 0.81 | KMT2A (0.55) | KMT2ATSHRMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL13495322 | 0.79 | BRD4 (0.56) | KMT2ATSHRMEN1BRD4 | |
| SCHEMBL13495369 | 0.78 | CYP19A1 (0.45) | KMT2ATSHRMEN1L3MBTL1CYP19A1 | |
| SCHEMBL15264731 | 0.77 | KMT2A (0.51) | KMT2ATSHRMEN1SMN1; SMN2L3MBTL1 | |
| Phensuximide SCHEMBL35334 | 0.77 | KMT2A (1.00) | KMT2ATSHRMEN1SMN1; SMN2L3MBTL1 | |
| Phensuximide SCHEMBL35333 | 0.77 | KMT2A (1.00) | KMT2ATSHRMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL13495376 | 0.75 | CYP19A1 (0.38) | KMT2ATSHRCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329377-B2 | Imide compound and chemically amplified resist composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100028807-A1 | Imide Compound and Chemically Amplified Resist Composition Containing The Same | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028807-A1 | Imide Compound and Chemically Amplified Resist Composition Containing The Same | IGF1R, CCNA1, MYC | KMT2A 219/4885TSHR 2519/4885MEN1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.